FDA: Oncology Radiopharmaceutical Labeling Must Include Genotoxicity

Drug Industry Daily
A A
Labeling for oncology radiopharmaceuticals must include information on the potential for genotoxicity and adverse reproductive toxicity, the FDA said in new draft guidance.

To View This Article:

Login

Subscribe To Drug Industry Daily